Claims for Patent: 9,668,915

Summary for Patent: 9,668,915

Title:	Drug eluting ocular implant
Abstract:	Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
Inventor(s):	Haffner; David (Mission Viejo, CA), Curry; Ken (Oceanside, CA), Heitzmann; Harold (Irvine, CA), Applegate; David (Laguna Hills, CA)
Assignee:	DOSE MEDICAL CORPORATION (San Clemente, CA)
Application Number:	13/989,037
Patent Claims:	1. A drug delivery ocular implant comprising: an elongate outer shell having a proximal end, a distal end, said outer shell being shaped to define an interior lumen; at least a first active drug positioned within said interior lumen, wherein said first active drug is present as one or more micro-tablets, wherein said micro-tablets have a density of about 0.7 g/cc to about 1.6 g/cc, wherein said outer shell comprises a first thickness; and wherein said outer shell comprises one or more regions of drug release, wherein the one or more regions of drug release comprise one or more orifices, wherein at least one of the one or more orifices comprises a hydrogel plug in or adjacent to the orifice, and wherein the first active drug passes through the hydrogel plug as it elutes from the implant the hydrogel plug thereby at least in part defining an elution rate of the first active drug from the implant. 2. The implant of claim 1, wherein said micro-tablets have a minor axis of about 0.28 to 0.31 mm and a major axis of about 0.8 to 1.1 mm. 3. The implant of claim 1, wherein said elongate shell is formed by extrusion. 4. The implant of claim 1, wherein said elongate shell comprises a biodegradable polymer. 5. The implant of claim 1, wherein said first active drug is present in an amount of at least 70% by weight of a total weight of the one or more micro-tablets, wherein said micro-tablets have a surface area to volume ratio of about 13 to 17, and wherein said micro-tablets have an aspect ratio of length to diameter of about 2.8 to 3.6. 6. The implant of claim 1, wherein said micro-tablets are configured to balance osmotic pressure between said interior lumen and the ocular environment external to an implant after implantation. 7. The implant of claim 1, wherein said micro-tablets are coated with a polymeric coating that regulates the release of said first active drug from said micro-tablet. 8. The implant of claim 1, wherein said outer shell is permeable or semi-permeable to said first active drug, thereby allowing at least about 5% of total the elution of the first active drug to occur through the portions of the shell having said first thickness. 9. The implant of claim 1, wherein said first active drug is an anti-angiogenesis agent selected from the group consisting of angiostatin, anecortave acetate, thrombospondin, VEGF receptor tyrosine kinase inhibitors and anti-vascular endothelial growth factor (anti-VEGF) drugs. 10. The implant of claim 9, wherein said anti-VEGF drugs are selected from the group consisting of ranibizumab, bevacizumab, pegaptanib, sunitinib and sorafenib. 11. The implant of claim 1, wherein said outer shell comprises a polysiloxane-containing polyurethane elastomer. 12. The implant of claim 1, wherein said regions of drug release are configured to allow a different rate of drug elution as compared to said elution through the outer shell, and wherein the overall rate of elution of said first active drug out of the implant is greater in the distal region of the implant. 13. The implant of claim 1, wherein the hydrogel plug is not biodegradable. 14. The implant according to claim 1, wherein the elution of said first active drug from said implant continues for at least a period of at least one year. 15. The implant of claim 1, further comprising a lumen configured to transport ocular fluid from a first location in an eye to one or more other locations, thereby reducing intraocular pressure. 16. The implant of claim 1, wherein the first active drug comprises a protein therapeutic. 17. The implant of claim 16, wherein the protein therapeutic is an anti-Vascular Endothelial Growth Factor (VEGF) antibody. 18. A method of treating an ocular condition or disorder in an intraocular target tissue comprising: making an opening in the temporal portion of an eye to access an anterior chamber of the eye; advancing a delivery device associated with the drug delivery ocular implant of claim 1 through the opening and across the anterior chamber of the eye, inserting the drug delivery ocular implant into eye tissue; positioning said implant such that at least one of said one or more regions of drug release are located proximate an intraocular target, the intraocular target is in the posterior chamber of the eye; and withdrawing the delivery device from the eye, wherein drug elutes from the implant in sufficient quantity to treat an ocular condition or disorder. 19. The method of claim 18, wherein the intraocular target is selected from the group consisting of the macula, the retina, the optic nerve, the ciliary body, and the intraocular vasculature. 20. The method of claim 18, wherein the first active drug elutes from the implant so as to achieve a therapeutic effect for a period of at least one year.

Details for Patent 9,668,915

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2031-11-22
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2031-11-22
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2031-11-22
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2031-11-22
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2031-11-22